Oaktree Capital Management LP acquired a new position in Mesoblast Limited (NASDAQ:MESO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 179,593 shares of the company's stock, valued at approximately $3,556,000. Oaktree Capital Management LP owned 0.14% of Mesoblast at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in shares of Mesoblast during the fourth quarter worth $30,000. Lindbrook Capital LLC lifted its holdings in Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after buying an additional 901 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Mesoblast during the 4th quarter valued at about $50,000. GAMMA Investing LLC boosted its position in Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock valued at $133,000 after buying an additional 1,213 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new position in Mesoblast in the 4th quarter worth about $134,000. 1.43% of the stock is owned by hedge funds and other institutional investors.
Mesoblast Trading Down 0.4 %
Shares of MESO stock traded down $0.05 during mid-day trading on Thursday, hitting $11.77. 89,758 shares of the stock traded hands, compared to its average volume of 304,643. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The stock's fifty day moving average is $15.97 and its two-hundred day moving average is $13.28. Mesoblast Limited has a 52-week low of $4.60 and a 52-week high of $22.00.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on MESO shares. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a report on Monday. Piper Sandler reiterated an "overweight" rating and issued a $24.00 target price (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Finally, Jefferies Financial Group lowered Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Stock Analysis on MESO
About Mesoblast
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
